

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

Scoping - Consultees recognised that, whilst prevalence of macular oedema is higher in people over the age of 50, this was not classed an equalities issue as it does not affect equality of access to treatment. Therefore no changes to the draft scope were necessary.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

The manufacturer commented that no recommended pharmacological treatment exists for patients with macular oedema following RVO. This was discussed by Committee: it agreed that it is not classed an equalities issue, since it did not apply to population groups protected by Equality legislation.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

No

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

No

Approved by Associate Director (name): Frances Sutcliffe

Date: 25 07 11

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a

specific group to access the technology compared with other groups?
If so, what are the barriers to access for the specific group?

No

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

No

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes in section X and the summary table

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 260711